Furthermore, with respect to CD38 inhibition, it would be nice to analyze the area of the big sample of myeloma patients (ranging over thousands) treated with anti-CD38 antibodies: At the moment there are only two approved antibodies, one with total blocking NADase activity (59–61) and a second with partial inhibition of ADP-ribosyl cyclase activity of human CD38 (62, 63). The gene discussed is CD38; the disease is plasma cell myeloma.